GSK has upgraded its longstanding alliance with CureVac on mRNA-based vaccines for respiratory infections, paying €400 million ($429 million) upfront for global rights to its influenza and COVID ...

Over the past two decades, I’ve observed significant shifts in the life sciences, pharmaceutical, and CDMO landscape. Pharmaceutical companies and their outsourcing partners must continuously ...